Hepatitis C
Newsletter
November 2012
Clinical
Trials, Cohort Studies, Pilot Studies
Efficacy
of pegylated interferon alpha-2b and ribavirin treatment on the risk of
hepatocellular carcinoma of patients with chronic hepatitis C: A prospective,
multicenter study. Ogawa
E, Furusyo N, Kajiwara E, et al. J Hepatol. 2012 Oct 22. pii: S0168-8278(12) 00816-1.
doi: 10.1016/j.jhep.2012.10.017. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23099187
Efficacy and Anticarcinogenic
Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated
Cirrhosis. Akuta N, Suzuki F, Seko Y, et al. Intervirology.
2012 Oct 4. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23037768
Risk factors for the exacerbation
of esophageal varices or portosystemic encephalopathy after sustained
virological response with IFN therapy for HCV-related compensated cirrhosis. Nagaoki
Y, Aikata H, Kobayashi T, J Gastroenterol. 2012 Oct 5. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23053422
Association of IL28B genotype and
viral response of hepatitis C virus genotype 2 to interferon plus ribavirin
combination therapy. Akuta N, Suzuki F, Seko Y, et al. J Med Virol. 2012
Oct;84(10):1593-9. doi: 10.1002/jmv.23368.
http://www.ncbi.nlm.nih.gov/pubmed/22930507
Does
IL28B genotyping still have a role in the era of direct-acting antiviral
therapy for chronic hepatitis C infection? Holmes JA, Desmond PV, Thompson AJ. J Viral Hepat.
2012 Oct;19(10):677-84. doi: 10.1111/jvh.12003.
http://www.ncbi.nlm.nih.gov/pubmed/22967098
Longitudinal liver stiffness
assessment in patients with chronic hepatitis C undergoing antiviral therapy. Martinez
SM, Foucher J, Combis JM, et al. PLoS One. 2012;7(10):e47715. doi:
10.1371/journal.pone.0047715. Epub 2012 Oct 17.
http://www.ncbi.nlm.nih.gov/pubmed/23082200
Race- and gender-related
variation in natural killer p46 expression associated with differential
anti-hepatitis c virus immunity. Golden-Mason L, Stone AE, Bambha KM, Cheng L, Rosen
HR. Hepatology. 2012 Oct;56(4):1214-22. doi: 10.1002/hep.25771.
http://www.ncbi.nlm.nih.gov/pubmed/22505144
Mutations in different regions of
the genome of hepatitis C virus genotype 1b and association with response to
interferon therapy. Zhang L, Han F, Zhang D, Dou XG. Int J Mol Med. 2012
Oct 15. doi: 10.3892/ijmm.2012.1155. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23064792
Racial
differences in the association between adiposity measures and the risk of
hepatitis C-related liver disease. White
DL, Tavakoli-Tabasi S, Kuzniarek J, Ramsey DJ, El-Serag HB. J Clin
Gastroenterol. 2012 Oct;46(9):779-88.
http://www.ncbi.nlm.nih.gov/pubmed/22955261
Tyrosine metabolism during
interferon-alpha administration: Association with fatigue and CSF dopamine
concentrations. Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison
DG, Raison CL, Miller AH. Brain Behav Immun. 2012 Oct 13. pii:
S0889-1591(12)00472-2. doi: 10.1016/j.bbi.2012.10.010. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23072726
Boceprevir With Peginterferon
Alfa-2a-Ribavirin Is Effective for Previously Treated Chronic Hepatitis C
Genotype 1 Infection. Flamm SL, Lawitz E, Jacobson I, et al. Clin
Gastroenterol Hepatol. 2012 Oct 10. pii: S1542-3565(12)01160-3. doi:
10.1016/j.cgh.2012.10.006. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23064222
The role of serum cytokines in
the pathogenesis of hepatic osteodystrophy in male cirrhotic patients. Soylu
AR, Tuglu C, Arikan E, et al. Gastroenterol Res Pract. 2012;2012:425079. doi:
10.1155/2012/425079. Epub 2012 Oct 14.
http://www.ncbi.nlm.nih.gov/pubmed/23097664
Basic
and Applied Science, Pre-Clinical Studies
Evaluation
of IL-28B Polymorphisms and Serum IP-10 in Hepatitis C Infected Chimpanzees. Verstrepen BE, de Groot NG,
Groothuismink ZM, et al. PLoS One. 2012;7 (10):e46645. doi:
10.1371/journal.pone.0046645. Epub 2012 Oct 30.
http://www.ncbi.nlm.nih.gov/pubmed/23118858
Single
nucleotide polymorphisms in GALNT8 are associated with response to interferon
therapy for chronic hepatitis C. Nakano
R, Maekawa T, Abe H, et al. J Gen Virol. 2012 Oct 3. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23034592
25-hydroxyvitamin
D(3) suppresses hepatitis C virus production. Matsumura T, Kato T, Sugiyama N, et
al. Hepatology. 2012 Oct;56(4):1231-9. doi: 10.1002/hep.25763.
http://www.ncbi.nlm.nih.gov/pubmed/22487892
HIV/HCV
Coinfection
Evaluation and treatment of
hepatitis C in patients with human immunodeficiency virus.
Bakaj
G, Valasiuk T, Prabhukhot R, Siraj D. South Med J. 2012 Oct;105(10):500-3. doi:
10.1097/SMJ.0b013e3182675d86.
http://www.ncbi.nlm.nih.gov/pubmed/23038477
Interleukin 28B rs12979860
(CT/TT) Genotype Is Associated with Milder Hepatic Damage in the Natural
Evolution of HCV/HIV Coinfection. de la Fuente C, Hinojosa C, Gilabert I, et al. J
Interferon Cytokine Res. 2012 Oct 2. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23030669
Low vitamin D levels are
associated with impaired virologic response to PEGIFN+RBV therapy in HIV/HCV
coinfected patients. Mandorfer M, Reiberger T, Payer BA, et al. AIDS.
2012 Oct 1. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23032421
Impact of hepatitis B and C
co-infection on health-related quality of life in HIV positive individuals. Gillis
J, Cooper C, Rourke S, et al. Qual Life Res. 2012 Oct 17. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23070749
Baseline risk factors for relapse
in HIV/HCV co-infected patients treated with PEG-IFN/RBV. Rivero-Juarez
A, Mira JA, Camacho A, et al. Infection. 2012 Oct 14. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23065463
IL28B polymorphisms are
associated with severity of liver disease in human immune-deficiency virus
(HIV) patients coinfected with hepatitis C virus. Guzmán-Fulgencio
M, Berenguer J, García-Álvarez M, et al. J Infect. 2012 Oct 25. pii:
S0163-4453(12)00311-8. doi: 10.1016/j.jinf.2012.10.025. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23103287
Risk of hip fracture associated
with hepatitis c virus infection and hepatitis C/human immunodeficiency virus
coinfection. Lo Re V 3rd, Volk J, Newcomb CW, et al. Hepatology.
2012 Nov;56(5):1688-98. doi: 10.1002/hep.25866. Epub 2012 Oct 14.
http://www.ncbi.nlm.nih.gov/pubmed/22619086
IL28B polymorphism is not
associated with HCV protease diversity in patients co-infected with HIV and HCV
treated with pegylated interferon and ribavirin. Osinusi
A, Chary A, Winters MA, et al. J Med Virol. 2012 Oct;84(10):1522-7. doi:
10.1002/jmv.23376.
http://www.ncbi.nlm.nih.gov/pubmed/22930497
Lack of a Clinically Significant
Drug-Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus
Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir. de
Kanter CT, Blonk MI, Colbers AP, Schouwenberg BJ, Burger DM. Clin Infect Dis.
2012 Oct 19. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23001704
Complementary
and Alternative Medicine
Anti-infective properties of
Epigallocatechin-3-gallate (EGCG), a component of Green Tea.
Steinmann
J, Buer J, Pietschmann T, Steinmann E. Br J Pharmacol. 2012 Oct 16. doi:
10.1111/bph.12009. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23072320
Epidemiology,
Diagnostics, and Miscellaneous Works
Baseline Characteristics and
Mortality Among People in Care for Chronic Viral Hepatitis: The Chronic
Hepatitis Cohort Study. Moorman AC, Gordon SC, Rupp LB, et al. Clin Infect
Dis. 2012 Oct 26. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22990852
Unhealthy
Alcohol Use, HIV Infection and Risk of Liver Fibrosis in Drug Users with
Hepatitis C. Muga
R, Sanvisens A, Fuster D, et al. PLoS One. 2012;7(10):e46810. doi:
10.1371/journal.pone.0046810. Epub 2012 Oct 9.
http://www.ncbi.nlm.nih.gov/pubmed/23056462
Stochastic
modeling of intra-household transmission of hepatitis C virus: evidence for
substantial non-sexual infection. Akhtar
S, Carpenter TE. J Infect. 2012 Oct 25. pii: S0163-4453(12)00306-4. doi:
10.1016/j.jinf.2012.10.020. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23103288
Impact
of disease severity on healthcare costs in patients with chronic hepatitis C
(CHC) virus infection. Gordon
SC, Pockros PJ, Terrault NA, et al. Hepatology. 2012 Nov;56(5):1651-60. doi:
10.1002/hep.25842. Epub 2012 Oct 9.
http://www.ncbi.nlm.nih.gov/pubmed/22610658
Concurrent
group treatment for hepatitis C: Implementation and outcomes in a methadone
maintenance treatment program. Stein
MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. J Subst Abuse
Treat. 2012 Dec;43(4):424-32. doi: 10.1016/j.jsat.2012.08.007. Epub 2012 Oct 2.
http://www.ncbi.nlm.nih.gov/pubmed/23036920
Knowledge,
attitudes and barriers regarding vaccination against hepatitis A and B in
patients with chronic hepatitis C virus infection: a survey of family medicine
and internal medicine physicians in the United States. Tenner CT, Herzog K, Chaudhari S,
Bini EJ, Weinshel EH. Int J Clin Pract. 2012 Oct;66(10):1009-13. doi:
10.1111/ijcp.12013.
http://www.ncbi.nlm.nih.gov/pubmed/22994334
The
Impact of Ethnicity on Hepatitis C Virus Treatment Decisions and Outcomes. Lisker-Melman M, Walewski JL. Dig
Dis Sci. 2012 Oct 12. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23065087
Comparison
of hepatitis C virus treatment between incarcerated and community patients.
Rice JP, Burnett D, Tsotsis H, et
al. Hepatology. 2012 Oct;56(4):1252-60. doi: 10.1002/ hep.25770.
http://www.ncbi.nlm.nih.gov/pubmed/22505121
Hepatitis
B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors
Associated With Testing and Infection Prevalence. Spradling PR, Rupp L, Moorman AC,
et al. Clin Infect Dis. 2012 Oct;55(8):1047-1055. Epub 2012 Aug 8.
http://www.ncbi.nlm.nih.gov/pubmed/22875876
Liver
Cancer
The
role and clinical implications of microRNAs in hepatocellular carcinoma. Zhao X, Yang Z, Li G, et al. Sci
China Life Sci. 2012 Oct;55(10):906-19. doi: 10.1007/s11427-012-4384-x. Epub
2012 Oct 31.
http://www.ncbi.nlm.nih.gov/pubmed/23108868
Promotion
of hepatocellular carcinoma by hepatitis C virus. Bühler S, Bartenschlager R. Dig
Dis. 2012;30(5):445-52. doi: 10.1159/000341688. Epub 2012 Oct 24.
http://www.ncbi.nlm.nih.gov/pubmed/23108300
Prognosis
of Patients with Hepatocellular Carcinoma. Validation and Ranking of
Established Staging-Systems in a Large Western HCC-Cohort. Op den Winkel M, Nagel D, Sappl
J, et al. PLoS One. 2012;7(10):e45066. doi: 10.1371/journal.pone.0045066. Epub
2012 Oct 5.
http://www.ncbi.nlm.nih.gov/pubmed/23071507
Hepatocellular
carcinoma risk prediction model for the general population: the predictive
power of transaminases. Wen
CP, Lin J, Yang YC, et al. J Natl Cancer Inst. 2012 Oct 17;104(20):1599-611.
doi: 10.1093/jnci/djs372.
http://www.ncbi.nlm.nih.gov/pubmed/23073549
Multiplicative
synergistic risk of hepatocellular carcinoma development among hepatitis B and
C co-infected subjects in HBV endemic area: a community-based cohort study.
Oh JK, Shin HR, Lim MK, et al. BMC
Cancer. 2012 Oct 5;12(1):452. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23039099
Association
of XRCC1, XRCC3, and XPD genetic polymorphism with an increased risk of
hepatocellular carcinoma because of the hepatitis B and C virus. Gulnaz A, Sayyed AH, Amin F, et
al. Eur J Gastroenterol Hepatol. 2012 Oct 5. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23044807
The
anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Cabrera R,
Limaye AR, Horne P, et al. Aliment Pharmacol Ther. 2012 Oct 24. doi:
10.1111/apt.12098. [Epub ahead of print]